CA
NZ
UK
AU
IND
US
aTyr Pharma (NASDAQ:ATYR) has made a decisive, high-risk choice: shrink the company dramatically to concentrate its resources on a single lead drug and the regulatory decisions that will define its future. The clinical-stage biotech announced a sweeping restructuring in August 2026 as it doubles …
● CEL-SCI announced plans to launch an FDA registration-enabling Phase 3 confirmatory study for Multikine, with reporting pointing to a study of roughly 212 patients.
●Phase 3 miss:On February 23, 2026, Gossamer announced that the Phase 3 PROSERA study of seralutinib did not meet its primary endpoint with statistical significance.
● ImageneBio's lead program, IMG-007, is an antibody being developed for atopic dermatitis and potentially other immune-mediated diseases.
Seres Therapeutics (NASDAQ:MCRB) is a pioneer in the emerging field of live biotherapeutic products, medicines made from communities of bacteria, now concentrating its efforts on a candidate designed to prevent dangerous infections in vulnerable patients. The company is balancing promising clinical data against a …
IceCure Medical (NASDAQ:ICCM) is building the kind of early commercial momentum that can change how investors view a small medical-device company. The Israel-based maker of cryoablation systems, technology that destroys tumors by freezing them, has been expanding its U.S. presence rapidly since securing a …
●Telehealth access:On July 6, 2026, LENZ announced a new telehealth prescribing option intended to accelerate patient access to VIZZ.
●New licensing deal:On August 11, 2026, Mereo announced an option and license agreement with Sentynl Therapeutics covering U.S. rights to alvelestat.
● enVVeno reported second-quarter 2026 financial results and advances toward an FDA pivotal trial for its first-in-class replacement venous valve.
Phreesia (NYSE:PHR), a healthcare-technology company that helps medical practices manage patient intake, scheduling and payments, has reached an important milestone: profitability. After years of prioritizing growth, the company crossed into positiveNet Incomewhile continuing to expand revenue.
Please wait processing your request...